




RealRate

# PHARMACEUTICAL 2020

Karyopharm Therapeutics Inc.  
Rank 240 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is -280%, being 23% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	278,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,350
Liabilities, Non-Current	13,202
Other Assets	13,347
Other Compr. Net Income	207
Other Expenses	2,447
Other Liabilities	185,637
Other Net Income	-10,275
Property and Equipment	3,046
Research and Development	122,340
Revenues	40,893
Selling, General and Administrative Expense	105,421

Output Variable	Value in 1000 USD
Assets	294,963
Liabilities	245,189
Expenses	230,208
Stockholders Equity	49,774
Net Income	-199,590
Comprehensive Net Income	-199,486
Economic Capital Ratio	-280%